A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

NCT06389214 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease

Interventions

DRUG: Reproxalap Ophthalmic Solution (0.25%)
DRUG: Vehicle Ophthalmic Solution

Sponsor

Aldeyra Therapeutics, Inc.